SMCC-DM1 is primarily used in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It serves as a linker molecule that connects a cytotoxic drug (DM1) to a monoclonal antibody, enabling the precise delivery of the drug to cancer cells. This targeted approach minimizes damage to healthy cells, reducing side effects compared to traditional chemotherapy. SMCC-DM1 is particularly valued for its stability in the bloodstream, ensuring the cytotoxic agent reaches the tumor site effectively. Its application is critical in advancing personalized medicine and improving treatment outcomes for various cancers.